Lei Jin

Oncology · Cancer Cell · 2011–2016

A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Lei Jin trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll (in Immunology)

Papers from Lei Jin's perspective

Ordered by how strongly the researchers Lei Jin trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  4. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
  5. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
  6. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  7. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (Journal of Experimental Medicine)
  8. Programmed death ligand-1 expression in non-small cell lung cancer (Laboratory Investigation)
  9. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (New England Journal of Medicine)
  10. hDOT1L links histone methylation to leukemogenesis. (Cell)

Their papers